Background-Cardiac hypertrophy is characterized by transcriptional reprogramming of fetal gene expression, and histone deacetylases (HDACs) are tightly linked to the regulation of those genes. We previously demonstrated that activation of HDAC2, 1 of the class I HDACs, mediates hypertrophy. Here, we show that casein kinase-2␣1 (CK2␣1)-dependent phosphorylation of HDAC2 S394 is required for the development of cardiac hypertrophy. Methods and Results-Hypertrophic stimuli phosphorylated HDAC2 S394, which was necessary for its enzymatic activation, and therefore the development of hypertrophic phenotypes in rat neonatal cardiomyocytes or in isoproterenoladministered mice hearts. Transgenic mice overexpressing HDAC2 wild type exhibited cardiac hypertrophy, whereas those expressing phosphorylation-resistant HDAC2 S394A did not. Compared with that in age-matched normal human hearts, phosphorylation of HDAC2 S394 was dramatically increased in patients with hypertrophic cardiomyopathy. Hypertrophy-induced phosphorylation of HDAC2 S394 and its enzymatic activity were completely blocked either by CK2 blockers or by CK2␣1 short interfering RNA. Hypertrophic stimuli led CK2␣1 to be activated, and its chemical inhibitors blocked hypertrophy in both phenylephrine-treated cardiomyocytes and isoproterenol-administered mice. CK2␣1-transgenic mice developed hypertrophy, which was attenuated by administration of trichostatin A, an HDAC inhibitor. Overexpression of CK2␣1 caused hypertrophy in cardiomyocytes, whereas chemical inhibitors of both CK2 and HDAC as well as HDAC2 S394A blunted it. Hypertrophy in CK2␣1-transgenic mice was exaggerated by crossing these mice with wild-type-HDAC2-overexpressing mice. By contrast, however, it was blocked when CK2␣1-transgenic mice were crossed with HDAC2 S394A-transgenic mice. Conclusions-We have demonstrated a novel mechanism in the development of cardiac hypertrophy by which CK2 activates HDAC2 via phosphorylating HDAC2 S394. (Circulation. 2011;123:2392-2403.)
C ardiac hypertrophy, an increase in the size of cardiomyocytes, is often caused by diverse pathological conditions such as myocardial infarction, hypertension, aortic stenosis, and valvular dysfunction. Although cardiac hypertrophy itself is an initial adaptive process, uncorrected continuous stimuli often lead the heart to heart failure. Because heart failure is a main cause of human mortality, many researchers are eager to develop interventions to reverse cardiac hypertrophy or to prevent the transition to congestive heart failure.
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Posttranslational modifications of histones are closely involved in diverse biological processes through the regulation of transcription of downstream target genes. 1, 2 Among these modifications, the acetylation status of the chromatin mediates the epigenetic regulation of gene expression. Two opposing groups of enzymes, histone acetyltransferase and histone deacetylases (HDACs), regulate the acetylation of histone. Recent evidence has demonstrated that HDACs are closely involved in diverse heart diseases, such as arrhythmia, heart failure, and acute coronary syndromes, as well as in cardiac hypertrophy. [3] [4] [5] [6] [7] Histone deacetylases can be divided into 4 families depending on their structure or tissue distributions. Among those families, class II HDACs (HDAC4, HDAC5, HDAC7, and HDAC9) were first highlighted as antihypertrophic mediators 8 that inhibit hypertrophy-associated genes by phosphorylation-dependent shuttling. 9 However, we and others demonstrated that HDAC2, 1 of the class I HDACs, is activated during cardiac hypertrophy 10 and mediates hypertrophy by modulating inositol polyphosphate-5-phosphatase f/glycogen synthase kinase 3␤ signals. In addition, we showed that Krüppel-like factor 4 (KLF4) is a downstream target of activated HDAC2 and that it works as a novel antihypertrophic mediator. 11 However, the upstream signal pathways that activate HDAC2 in response to hypertrophic stimuli have not yet been elucidated. In this study, we hypothesized that the phosphorylation of HDAC2 might be important for its enzymatic activation in response to hypertrophic stimuli and observed that casein kinase-2 (CK2), a novel prohypertrophic mediator, is an upstream regulatory molecule that induces the phosphorylation and activation of HDAC2.
Methods

Transgenic Mice
␣-Myosin heavy chain (U71441) promoter-driven transgenic mice were generated by a commercial company (Macrogen, Seoul, Korea) on the C57BL/6 background in accordance with National Institutes of Health guidelines. All experimental procedures were approved by the Chonnam National University Medical School Research Institutional Animal Care and Use Committee.
Leucine Incorporation
Incorporation of [ 3 H]-leucine was measured as described. 11, 12 In Vitro Kinase Assay
The in vitro kinase assay was performed as described 13 with slight modifications.
CK2 Assay
The CK2 assay was done with a commercially available kit (Upstate Biotechnology Inc, Lake Placid, NY).
Human Samples
Autopsied left ventricle specimens were obtained from 6 individuals: 3 hypertrophied and 3 age-matched males. Hypertrophic cardiomyopathy was diagnosed according to total heart weight, left ventricular free wall thickness, and microscopic findings. This work was performed according to the regulations of the institutional review board of Chonnam National University Hospital (No. 2010-10-167).
Statistical Analysis
The data were analyzed by use of either the unpaired Student t test or 1-way ANOVA, which was followed by the Reagents and all other experimental procedures are described in the online-only Data Supplement.
Results
Histone Deacetylases 2 S394 Is Phosphorylated by Hypertrophic Stresses
Phosphorylation of HDACs is often associated with their activation by increasing their intrinsic enzymatic activity 14, 15 or by promoting their translocation into the nucleus. 8 Thus, we first checked whether HDAC2 is phosphorylated in cardiac hypertrophy. As determined by use of antiphosphoserine antibody after immunoprecipitation with HDAC2, the amount of phosphorylated serine was increased by endothelin-1 or isoproterenol in both cardiomyocytes and mouse heart ( Figure 1A and 1B and Figure I in the onlineonly Data Supplement). HDAC2 has been reported to have 3 different levels of phosphorylation, 16 and in our study we observed 3 different molecular weights of endogenous HDAC2. Interestingly, only the hyperphosphorylated form of HDAC2 was upregulated in isoproterenol-administered mouse hearts ( Figure 1C , top panel).
Both a previous report 17 and prediction from the phosphobase Web site (http://elm.eu.org/) indicated that the S394, S411, S422, and S424 residues of HDAC2 can be phosphorylated. To determine which serine residues are responsible for the hypertrophy-associated phosphorylation, we next performed an in vitro kinase assay with synthetic peptides, as indicated in Figure 1D . Hypertrophic stress with phenylephrine increased the phosphorylation at S394 and S411 in cardiomyocytes, whereas it failed to do at S422 or S424 ( Figure 1D ). The results were the same in an experiment with an in vivo isoproterenol infusion pump mouse model ( Figure  II in the online-only Data Supplement). To rule out other phosphorylation sites in the HDAC2 molecule, we used glutathione-S-transferase (GST) fusion proteins of HDAC2 wild-type (WT) and mutant forms of HDAC2 S394A and HDAC2 S394/411/422/424A for an in vitro kinase assay. No phosphorylation was observed with the HDAC2 S394/411/ 422/424A mutant, which indicated that no phosphorylation of residues other than those residues takes place ( Figure 1E ). We also used a phospho-specific antibody against HDAC2 pS394. In isoproterenol-treated heart, a greater amount of phosphorylation was detected ( Figure 1C , bottom panel). Likewise, 20% fetal bovine serum (FBS) stimulation dramatically increased the phosphorylation of HDAC2 S394 ( Figure  1F and Figure III in the online-only Data Supplement). Alternate hypertrophic stresses of endothelin-1 ( Figure 1G ) or phenylephrine ( Figure 1H ) also significantly increased the pS394 HDAC2 amount. In summary, both the S394 and S411 residues were phosphorylated by hypertrophic stresses both in vivo and in vitro.
Phosphorylation of Histone Deacetylases 2 S394 Is Required for Hypertrophy
We next examined whether the phosphorylation of HDAC2 is essential for cardiac hypertrophy. We first used HDAC2 S394A, S411A, S422/424A, and S394/411/422/424A mutant forms of pcDNA3.1-HDAC2-V5 constructs for an HDAC assay after immunoprecipitation with V5 antibody. Substitution of S394 with alanine significantly reduced the enzymatic activity. In addition, both S422 and S424 residues were critical for the maintenance of enzymatic activity. Interestingly, HDAC2 S411A had enzymatic activity equivalent to the WT (Figure 2A ). The observations that hypertrophic stresses induce phosphorylation of S394 and S411 ( Figure 1 ) and that enzymatic activation requires S394, S422, and S424 ( Figure 2A ) indicated that S394 is the serine residue respon-sible for the hypertrophy-associated activation of HDAC2, whereas intrinsic basal activity is maintained by S422 and S424.
The association of HDAC2 S394 but not S411 with hypertrophy was further confirmed by promoter analysis. Four-fold activation of the promoter of natriuretic peptide precursor type A (Nppa; encoding atrial natriuretic factor), a marker of hypertrophy and failure, 18 was induced by cotransfection with HDAC2wt. However, activation of the Nppa promoter was significantly attenuated by transfection with HDAC2 S394A. Interestingly, substitution of S411 with alanine did not reduce the HDAC2-induced promoter activation ( Figure 2B ). In addition, HDAC2 S394A failed to increase the cardiomyocyte size ( Figure 2C and 2D), indicating that phosphorylation of S394 is required for the hypertrophic response.
We further confirmed the necessity of phosphorylation of HDAC2 S394 in an in vivo animal model. Two independent ␣-myosin heavy chain promoter-driven transgenic mouse lines 19 were generated that overexpressed either HDAC2wt-V5 or HDAC2 S394A-V5 in adult hearts. The expression levels of the WT and mutant proteins were evaluated for each transgenic line, and the transgenic lines expressing almost the same level of proteins were selected for further evaluation ( Figure 2F , top row).
As evaluated by the ratio of heart weight to tibia length, we observed that transgenic mice overexpressing HDAC2wt showed a dramatic increase in heart size, as reported previously. 20 Interestingly, the hypertrophic response was blunted when HDAC2 S394A was overexpressed in the heart ( Figure  2E ). Expression of atrial natriuretic factor ( Figure 2F , middle row) and the transcript level of skeletal ␣-actin ( Figure IV in the online-only Data Supplement) were not increased in transgenic (Tg)HDAC2 S394A compared with TgHDAC2wt. The quantitative results for the Nppa and Myh7 (encoding ␤-myosin heavy chain) transcripts are discussed below. The enzymatic activity of HDAC2 in the heart was also greatly reduced in TgHDAC2 S394A ( Figure 2G ).
Phosphorylation of HDAC2 S394 was further confirmed by using the samples obtained from patients with hypertrophic cardiomyopathy. First, we performed immunohistochemistry analysis using HDAC2 pS394-specific antibody. Compared with that in age-matched normal heart, the phosphorylation of HDAC2 was significantly increased in hypertrophic heart (Figure 2H ). The level of protein phosphorylation was also examined by Western blot analysis with the samples obtained from 3 individuals, and the phosphorylation of HDAC S394 was significantly increased in the heart samples from all 3 hypertrophic cardiomyopathy patients ( Figure 2I ).
CK2 Phosphorylates and Activates Histone Deacetylases 2
We next searched for the protein kinase responsible for the phosphorylation and activation of HDAC2. First, we per- formed an in vitro kinase assay with a synthetic peptide of S394 with various protein kinase inhibitors (data not shown). Of the protein kinases tested, a series of CK2 inhibitors such as apigenin and the more selective 4,5,6,7-tetrabromobenzotriazole (TBB) and (E)-3-(2,3,4,5-tetrabromophenyl) acrylic acid (TBCA) successfully inhibited the phosphorylation of S394 induced by infusion of isoproterenol in mice ( Figure 3A) . The results were also repeated with in vitro cardiomyocyte mod- Figure 2 . Phosphorylation of histone deacetylase (HDAC)2 S394 is required for the development of cardiac hypertrophy. A, HDAC2 enzymatic activity was lost when serine 394 was substituted by alanine. Substitution of serine 411 with alanine did not reduce the enzymatic activity. B, HDAC2 S394 is important for the full activation of natriuretic peptide precursor type A (Nppa) promoter in cardiomyocytes. C and D, HDAC2 S394A failed to increase cardiomyocyte size (C). Cardiomyocytes were transfected with either wild-type (WT) or S394A construct, and the areas of transfected cells were counted (D). E, Cardiac hypertrophy was blunted in HDAC2 S394A-overexpressing mouse hearts compared with HDAC2 WT-overexpressing mice. Horizontal bars indicate the mean of each group, and dots represent heart weight/tibia length ratio values of individual animals. F, Expression of atrial natriuretic factor (ANF) was blunted in transgenic (Tg)HDAC2 S394A compared with TgHDAC2wt. Expressions of HDAC2WTand S394A were equal in those 2 separate lines. G, HDAC2 enzymatic activity was not increased in TgHDAC2 S394A hearts. H, The amount of HDAC2 pS394 was markedly increased in the heart sections obtained from hypertrophic cardiomyopathy (HCMP) patients compared with age-matched normal hearts. Immunohistochemistry was performed with anti-HDAC2 pS394 antibody. I, The increase in the level of phosphorylation was further confirmed with immunoblot analysis with the use of anti-HDAC2 pS394 antibody. Autopsy samples of heart from 3 patients and 3 age-matched individuals were prepared for the analysis. *PϽ0.05; **PϽ0.01; @PϽ0.05; @@PϽ0.01. els. Phosphorylation by either FBS or phenylephrine was completely blocked by treatment of the cells with apigenin ( Figure 3B ). CK2 inhibitors also completely abolished the phosphorylation of GST-HDAC2 induced by applying heart lysates from isoproterenol-administered mice ( Figure 3C ). Blockade of the phosphorylation of HDAC2 S394 by TBB was further repeated in rat neonatal cardiomyocytes; TBB significantly attenuated the amount of pS394 in FBS-or phenylephrine-treated cardiomyocytes, as determined by phospho-specific antibody ( Figure 3D ).
We next tested whether CK2 is required for the activation of HDAC2 by use of an HDAC2 activity analysis in the presence of CK2 inhibitor ( Figure 3E ) or CK2 short interfering (si)RNA ( Figure 3F ). As we reported previously, 10 the intrinsic activity of the chimeric protein of GST-HDAC2 was greatly increased when isoproterenol-treated heart lysates were applied to the proteins (column 4 in Figure 3E ). The activation was completely blocked when TBB, TBCA, apigenin, and 2-dimethylamino-4,5,6,7-tetrabromo-1Hbenzimidazole (DMAT), an alternate CK2 inhibitor, were applied. However, other protein kinase inhibitors failed to attenuate the HDAC2 activation (columns 9 through 13). These results were also confirmed in the cardiomyocytes ( Figure 3F ). The FBS-induced activation of HDAC2 was significantly blocked by TBB (column 9). More specifically, downregulation of CK2␣1 by utilization of siRNA dramatically reduced FBS-stimulated (column 11) HDAC2 activity. In contrast, transfection of pCMV-HA-CK2␣1 mimicked the hypertrophic stress-induced activation of HDAC2 (column 7). Interestingly, however, CK2␣2 siRNA failed to inhibit the FBS-stimulated activation of HDAC2 (column 12).
Hypertrophic Stimuli Activate and Translocate CK2␣1
Next, we questioned whether CK2 activity is increased in response to hypertrophic stresses. We modified an in vitro kinase assay with specific peptides to measure CK2 enzyme activity. Phenylephrine, FBS, and isoproterenol significantly increased the CK2 activity in cardiomyocytes ( Figure 4A ) and in heart ( Figure 4B ). Previous reports have demonstrated that shuttling between the nucleus and the cytoplasm is also an important regulatory mechanism of CK2 activity in diverse biological responses. 21, 22 In contrast, Hauck et al 23 recently reported that CK2␣2 does not shuttle but phosphorylates p27 in the cytoplasm in response to hypertrophic stresses in cardiomyocytes. Thus, we checked whether our CK2␣1 follows the case of CK2␣2 by observing its intracellular distribution after treatment with the hypertrophic stimulus of FBS ( Figure 4C and 4D) . Although total amounts of CK2␣1 were not altered (top 2 panels), the amount of CK2␣1 in the nuclear fraction was increased (middle 2 panels), whereas that in the cytosolic fraction was reduced (bottom 2 panels). Immunocytochemical analysis showed increased nuclear localization after FBS stimulation ( Figure 4D) . These results suggest that in addition to its intrinsic activity, the translocation of CK2␣1 participates in the activation of HDAC2.
CK2␣1 Induces Cardiac Hypertrophy
We examined whether activation of CK2␣1 is responsible for relaying the hypertrophic phenotypes in cardiomyocytes and mouse heart. Transfection of pCMV-HA-CK2␣1 to cardiomyocytes significantly increased leucine incorporation. Furthermore, phenylephrine-or FBS-induced increases were markedly blocked by either CK2 inhibitors or transfection of CK2␣1 siRNA ( Figure 5A ). Both basal and phenylephrinestimulated Nppa promoter activity was inhibited by TBB in a dose-dependent fashion ( Figure 5B ).
We next investigated whether HDAC2 is an ultimate downstream of CK2␣1 to induce hypertrophic phenotypes. Both HDAC2 siRNA and trichostatin A completely blocked the CK2␣1-induced increase in leucine incorporation ( Figure  5C ). We reported previously that KLF4, a novel antihypertrophic mediator, is a downstream target of HDAC2 in the development of cardiac hypertrophy. 11 Thus, by utilizing KLF4-binding element disrupted Nppa promoter, 11 we investigated whether the CK2 inhibitor-induced effect is also KLF4 dependent. Treatment with either TBB or TBCA failed to reduce the mutant promoter activity ( Figure 5D ). These results suggest that CK2␣1-induced hypertrophic events are dependent on both HDAC2 and KLF4.
Transfection of CK2a1 siRNA completely blocked the Nppa promoter activity compared with that in scrambletreated cardiomyocytes ( Figure 5E ). The effect of CK2 inhibitor was also reiterated in vivo. Continuous infusion of isoproterenol induced cardiac hypertrophy, which was blunted by simultaneous intraperitoneal administration of apigenin ( Figure 5F ). Again, HDAC2 enzymatic activity in the mouse heart was significantly lowered in apigenin-treated mice ( Figure 5G ).
Transgenic Overexpression of CK2␣1 Induces Cardiac Hypertrophy
CK2␣1-overexpressing transgenic mice were generated to study whether CK2␣1 is prohypertrophic in vivo. Cardiac hypertrophy was evaluated by echocardiography; both the interventricular septum ( Figure 6A ) and the left ventricular free wall thickness ( Figure 6B) were increased in the transgenic mice. Other parameters are shown in the Table in the online-only Data Supplement. The protein amounts of skel-etal ␣-actin or ␣-tubulin were upregulated in CK2␣1transgenic mice. In addition, the phosphorylation of HDAC2 S394 was increased in those transgenic mice ( Figure 6C ). Cardiac hypertrophy in TgCK2␣1 mice was further confirmed by measuring heart weight; heart weight was greater in TgCK2␣1 mice than in wild-type littermate ( Figure 6D ). Again, we examined whether HDAC is downstream of CK2␣1 in vivo. Thus, we administered trichostatin A, an HDAC inhibitor, to TgCK2␣1 mice. Interestingly, cardiac hypertrophy induced by overexpression of CK2␣1 was completely blocked by trichostatin A (Figure 6D and Figure VA in the online-only Data Supplement). Quantification of the transcript levels of Nppa ( Figure 6E ) and skeletal ␣-actin (actin alpha 1 skeletal muscle [Acta1]; Figure VB 
CK2␣1-Induced Cardiac Hypertrophy Is Attenuated by Histone Deacetylases 2 S394A
Given that CK2␣1 induces HDAC2 phosphorylation and activation, a phosphorylation-resistant HDAC2 mutant may block CK2-induced hypertrophic phenotypes. We used a leucine incorporation study to check this hypothesis. As expected, cotransfection of CK2␣1 and HDAC2wt further increased the incorporation. However, transfection of HDAC2 S394A blocked CK2␣1-induced incorporation (Fig-Figure 6 . Casein kinase (CK)2␣1 is hypertrophic in vivo. A and B, Echocardiographic evaluation of transgenic (Tg)CK2␣1 hearts. Interventricular septum thickness (A) and left ventricular free wall thickness (B) were increased in TgCK2␣1 hearts. WT indicates wild type. C, Hypertrophic markers as well as phosphorylation of HDAC2 S394 were increased in TgCK2␣1 hearts. D, CK2␣1-mediated hypertrophy is histone deacetylase (HDAC) dependent. Overexpression of CK2␣1 in mouse heart induced cardiac hypertrophy, which was completely blocked by trichostatin A (TSA), an HDAC inhibitor. **PϽ0.01. E, Real-time reverse transcription polymerase chain reaction results showing the changes in natriuretic peptide precursor type A (Nppa) expression in TgCK2␣1ϩTSA mice. Because the data of E were not normally distributed as determined by the Shapiro-Wilk test, P value was obtained by the Mann-Whitney U test with Bonferroni correction. ¶, §PϽ0.0125.
ure 7A). Blockade of the CK2 effect by HDAC2 S394A was also observed by Nppa-or Myh7-promoter analysis ( Figure  7B and 7C) . We also evaluated cardiac hypertrophy by crossing TgCK2␣1 mice with TgHDAC2 S394A mice. We found that the cardiac enlargement was greatly exaggerated when TgCK2␣1 mice were crossed with TgHDAC2wt. Interestingly, however, no exaggeration of cardiac hypertrophy was observed when TgCK2␣1 mice were crossed with TgHDAC2 S394A (Figure 7D and Figure VIA also supported the results. Figure 7F shows that CK2␣1induced enlargement of individual cardiomyocyte area was further increased in Tg CK2␣1;HDAC2wt mice but not in Tg CK2 ␣1;HDAC2 S394A . We checked whether transgenic overexpression of CK2␣1 or HDAC2 causes hyperplasia rather than hypertrophy by counting proliferating cell nuclear antigen; however, we found no significant changes in the animal groups ( Figure VII in the online-only Data Supplement).
Discussion
We have established the existence of a previously undescribed signal pathway in the development of cardiac hypertrophy: that of CK2␣1-mediated phosphorylation of HDAC2 S394 and subsequent activation of HDAC2. When hypertrophic stimuli act on cardiomyocytes, the stimuli activate CK2, which then phosphorylates HDAC2 S394, and the resulting enzymatic activation of HDAC2 mediates the hypertrophic phenotype (Figure 8 ). All mammalian HDACs have potential phosphorylation sites, and phosphorylation is a key mechanism of regulating activity by modifying substrate specificity 17, 24 or by regulating stability with other corepressor complexes, such as RbAp48, MTA-2, mSin3A, and CoREST complex. 25 Although the phosphorylation of HDAC2 is known to be required for its association with mSin3 and Mi2 corepressors, 16, 17 the biological significance of the phosphorylation of HDAC2 and its activation is largely unknown. A recent study reported that phosphorylation of HDAC2 regulates corepressor formation and activates enzymatic activity in association with cigarette smoking. 26 In addition, the phosphorylation and activation of HDAC2 are closely associated with tumor cell progression 27 and metastasis. 28 Previous findings reported that phosphorylation on S394 is tightly related to complex formation 16, 17 and that deacetylation substrate is dissociated from HDAC2 after S424 phosphorylation. 29 We and others have shown the involvement of HDAC2 in cardiac hypertrophy. 10, 20 In the present study, we have shown for the first time that the hypertrophic stimuli-induced phosphorylation of HDAC2 is required for HDAC2 activation, and therefore for the development of cardiac hypertrophy. The enzymatic activity of HDAC2 was regulated by the S394, S422, and S424 residues, whereas hypertrophic stresses phosphorylated HDAC2 S394 and S411. These results suggest that only the phosphorylation of S394 is responsible for the enzymatic activation in association with hypertrophic stimuli, and that S422 and S424 are related to basal enzymatic activity but not hypertrophy-induced activity. Thus, hypertrophic stress-induced phosphorylation of HDAC2 S394 is a key regulatory mechanism in relaying hypertrophic phenotypes. Indeed, we also observed that phosphorylation of HDAC2 S394 takes place in heart samples obtained from hypertrophic cardiomyopathy patients. Although the biological significance of the phosphorylation of HDAC2 S411 should be investigated further, it can be assumed that this phosphorylation is related either to intracellular localization or to binding affinity for other transcription cofactors.
The implication of the biological roles of CK2 was first highlighted in cancer biology. CK2 levels are elevated in cancer tissues, 30 and inhibition of CK2 by selective blockers attenuates cell proliferation. 31 CK2 enhances the transforming potential of oncogenes, generates abnormal prosurvival and antiapoptotic signals, and supports neovascularization. CK2 has multiple target molecules in diverse tissues 32 because the substrate consensus protein sequence is ubiquitous in diverse cellular types. Growing numbers of reports have appeared dealing with the functional roles of CK2 in cardiac diseases. For example, some subtypes of CK2 are closely related to ischemia/reperfusion injury 33 and embryonic heart development. 34 Recently, CK2␣2 was shown to induce cardiac hypertrophy, which is mediated by the CK2␣2-dependent degradation of p27, 23 an important antihypertrophic cell cycle regulator. 35 That report clearly demonstrated that CK2␣2 is also a prohypertrophic mediator. However, the working mechanism was quite different from ours. In addition to the different target, those authors did not observe the shuttling of CK2␣2 in response to cardiac hypertrophy. Because many proteins could be substrates of CK2, it is likely that targets other than HDAC2 may participate in relaying the hypertrophic phenotypes. Indeed, we also observed that p27 was slightly downregulated in hypertrophic stresses in cardiomyocytes (data not shown). However, in our study, phosphorylation-resistant HDAC2 S394A blunted the CK2␣1-mediated cardiac hypertrophy, which strongly suggests that HDAC2 phosphorylation is a key regulatory mechanism of CK2␣1-induced cardiac hypertrophy.
It would be interesting to determine whether phosphorylated HDAC2 is associated with other hypertrophy-associated proteins that can be altered by diverse stresses to cardiomyocytes. Indeed, some hypertrophy-related factors preferentially bind to hyperphosphorylated HDAC2 (data not shown). We also observed that heat shock protein 70, which was reported as an HDAC2 activator by our group, 10 synergistically induced hypertrophic phenotypes together with phosphorylated HDAC2 (data not shown). These results suggest that HDAC2 phosphorylation and activation may be a complex process in the development of cardiac hypertrophy, although detailed mechanisms should be elucidated. In addition, the manner in which CK2␣1 is activated by hypertrophic stimuli should be clarified. It is known that signals such as Wnt, 36 UV irradiation, 37 or dysinhibition of p53 38 induce the activity of CK2␣1 in cancer. However, it is still unclear whether this signal cascade takes place in tumorigenesis in the same fashion as in the development of cardiac hypertrophy.
In summary, hypertrophic stress-induced activation of CK2␣1 phosphorylates HDAC2 S394, which results in the activation of HDAC2 enzymatic function to repress the expression of antihypertrophic genes. Note, however, that the CK2/HDAC2 signal is not the only mechanism in the development of cardiac hypertrophy. For instance, diverse traditional pathways like G-protein or calcium-dependent signals are well established in cardiac hypertrophy. However, when one considers that subtype-selective HDAC inhibitors and CK2 blockers are being investigated intensively as potential therapeutics for various diseases such as cancer 39 or inflammation, 40 our findings may provide valuable targets for the development of novel drugs for cardiac hypertrophy and heart failure.
Cardiac hypertrophy is a response to diverse forms of heart disease, including myocardial infarction, hypertension, and valvular dysfunctions. Although the initial hypertrophic responses are an adaptation to those stimuli, the sustained stress may lead to cardiomyopathy and heart failure, a major cause of human morbidity and mortality. Few interventions have proven effective in blocking hypertrophy or in preventing the transition to heart failure. Recently, transcriptional reprogramming of fetal gene expression by histone deacetylases was shown to be tightly linked to cardiac hypertrophy. We showed previously that inhibition of class I HDACs prevents cardiac hypertrophy and that activation of HDAC2, 1 of the class I HDACs, in association with heat shock protein 70, is essential for hypertrophy. In addition, we have reported that KLF4, a novel antihypertrophic mediator, relays the HDAC2 effects. Here we show that CK2␣1-dependent phosphorylation of HDAC2 S394 induces enzymatic activation of HDAC2 and thereby mediates hypertrophy. Interestingly, the phosphorylation of HDAC2 S394 was dramatically increased in hearts from hypertrophic cardiomyopathy patients. Hypertrophic stimuli led CK2␣1 to be activated, and overexpression of CK2␣1 caused cardiac hypertrophy both in vivo and in vitro, whereas chemical inhibitors of CK2␣1 blunted this response. Modulators of the activity of both CK2 and HDAC are under extensive investigation for widespread clinical use for noncardiac diseases, including neoplasia. Our work implicates CK2␣1/HDAC2 signal cascades as novel therapeutic targets for the treatment or prevention of cardiac hypertrophy and heart failure worthy of further validation and investigation.
